What To Know About UBS's Upgrade of Teva Pharmaceutical Indus
Portfolio Pulse from Benzinga Insights
UBS has upgraded Teva Pharmaceutical Industries (NYSE:TEVA) from a previous rating to Buy, with a new price target of $13.00, up from $11.00. Teva's shares have risen 2.62% in the last 24 hours to $9.80. The new price target suggests a potential upside of 32.65% from the current share price. Teva is a leading generic drug manufacturer with a significant market presence in North America, Europe, Japan, Russia, and Israel, and offers a range of generic and specialty drugs, as well as active pharmaceutical ingredients and contract manufacturing services.
November 27, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS upgraded Teva Pharmaceutical Industries to Buy with a new price target of $13.00, up from $11.00, representing a potential 32.65% increase from the current price of $9.80.
The upgrade by UBS to a Buy rating and the increase in price target to $13.00 are strong positive signals for Teva Pharmaceutical Industries, suggesting analyst confidence in the company's future performance. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100